SCHEMBL14701451

SCHEMBL14701451

CC(=O)Oc1ccc(C2Oc3cc(O)cc(O)c3C[C@H]2O)cc1OC(C)=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.65
KDM4E B2RXH2 5/20 0.65
PTGS1 P23219 5/20 0.65
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
ALDH1A1 P00352 4/20 0.65
GAA P10253 3/20 0.65
HSD17B10 Q99714 3/20 0.65
MAPT P10636 3/20 0.65
APEX1 P27695 3/20 0.65
RECQL P46063 3/20 0.65
CYP3A4 P08684 3/20 0.65
SNCA P37840 3/20 0.65
PKM P14618 2/20 0.65
PTGS2 P35354 2/20 0.65
ALPL P05186 2/20 0.65
POLB P06746 2/20 0.65
RAD52 P43351 2/20 0.65
HPGD P15428 2/20 0.65
ALOX15 P16050 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29105259 1.00 BACE1 (0.65) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL29682334 1.00 BACE1 (0.65) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL20169846 0.93 BACE1 (0.68) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL20169845 0.93 BACE1 (0.68) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL17509383 0.91 BACE1 (0.65) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL16151167 0.91 BACE1 (0.65) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL17523215 0.90 BACE1 (0.61) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL17509388 0.87 BACE1 (0.57) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL16160500 0.87 BACE1 (0.57) BACE1KDM4EPTGS1MEN1KMT2A
SCHEMBL5333406 0.85 BACE1 (0.70) BACE1KDM4EPTGS1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 US disclosed
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 US disclosed
WO-2013022846-A2 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256741-A1 FLAVONOID COMPOUNDS FIS1, TFAM, MFN2 BACE1 4428/4885KDM4E 1854/4885PTGS1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.